Relapsed data are uncompetitive, but the front-line PACC-mutant space offers hope.
ApexOnco Front Page
Recent articles
Cross-licensing pact brings in SKB105, and hands off China rights to CR-001 before first-in-human studies.
Adcetris bags its eighth approval, while SpringWorks and Ono also feature.
BGB-16673 and BGB-43395 will soon both be in phase 3 trials, BeiGene reveals.
Another SERD catalyst and the son of Darzalex take centre stage.
Tough equity markets as well as competitor developments prompt a narrowed focus.
The company hits an FDA-mandated enrolment target, but only in follicular lymphoma.
Giredestrant will soon become the first oral SERD to yield first-line data.
